Profound Medical Corp.PROF
時価総額
$2.3億
PER
切開不要の治療用組織アブレーション機器の新興企業。TULSA‑PROやSonalleveなどのプラットフォーム型アブレーションシステムを展開。2017年7月にSonalleve関連資産で買収、2019年10月にNASDAQ上場。カナダ本社を含む米国・欧州・中国を中心に展開。
| 2020年 12月31日 | 2022年 12月31日 | 2023年 12月31日 | 2024年 12月31日 | |
| Recurring - non-capital | - | - | - | 8 |
| Capital equipment | - | - | - | 2 |
| Revenues | 7 | 7 | 7 | 11 |
| Cost of sales | - | - | - | 4 |
| Gross profit | 3 | 3 | 4 | 7 |
| Research and development | 10 | 15 | 14 | 17 |
| Selling, general and administrative | - | - | - | 23 |
| Total operating expenses | - | - | - | 40 |
| Operating loss | -19 | -32 | -29 | -33 |
| Net finance (income) expense | - | - | - | 1 |
| Net foreign exchange (gain) loss | - | - | - | 4 |
| Total other (income) expenses | - | - | - | 5 |
| Net loss before income taxes | - | - | - | -28 |
| Current Income Tax Expense (Benefit) | - | - | - | 0 |
| Deferred tax expense (note 13) | - | - | - | -0 |
| Total income tax (recovery) expense | - | - | - | -0 |
| Net loss attributed to shareholders for the year | -22 | -29 | -29 | -28 |
| Foreign currency translation adjustment - net of tax | - | - | - | -3 |
| Net loss and other comprehensive loss for the year | - | - | - | -31 |
| Earnings Per Share, Basic | - | - | - | 1.12 |
| Earnings Per Share, Diluted | - | - | - | 1.12 |